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Abstract While biosimilars of low molecular-weight biol-
ogics such as G-CSF have been available in Europe since
2006, biosimilars of monoclonal antibodies (mAbs) have only
become available in the last year. Unlike G-CSF, mAbs are
large and complex and often play a direct role in the survival of
patients with life-threatening illnesses such as breast cancer.
Several biosimilars are currently under development for the
treatment of breast cancer, and the use of biosimilars in a
setting that directly impacts patient survival raises a number of
questions. In this review, we discuss the biosimilar mAbs
currently in development for the treatment of breast cancer.
We provide an overview of the European Medicine Agency
guidelines and historic data on the development of biosimilars
in order to discuss the development of biosimilar mAbs for
breast cancer. Biosimilars offer a highly attractive path toward
reducing the cost of medical care and should be pursued with
great interest. However, for agents used to treat life-threat-
ening diseases such as cancer, a cautious approach must be
taken to ensure that there is no negative impact on patient care.
Clinical trials for biosimilar mAbs must be carried out in an
appropriately sensitive patient population using endpoints that
can accurately demonstrate both the similarity of the bio-
similar and its efficacy in the indication. Due to the
abbreviated approval pathway, rigorous pharmacovigilance
must be in place once a biosimilar mAb is approved in order to
ensure its long-term safety and efficacy.
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The emergence of biosimilar antibodies in oncology
The discovery of the HER2 proto-oncogene and the devel-
opment of the HER2-targeted antibody trastuzumab (Her-
ceptin, Genentech) more than two decades ago represent
landmark achievements in the treatment of breast cancer.
Prior to trastuzumab, women with HER2-positive breast
cancer had few treatment options and progressed rapidly.
The introduction of trastuzumab in previously untreated
patients with metastatic disease resulted in a 4.8 month
increase in median overall survival (OS) [1]. Women with
HER2-positive metastatic breast cancer now have survival
rates similar to patients with hormone receptor–positive
breast cancer, a disease that historically had a more favor-
able prognosis. Trastuzumab has since been approved for
use in many indications, including neoadjuvant and adjuvant
breast cancer. In early breast cancer, one year of treatment
with adjuvant trastuzumab with chemotherapy results in a
statistically significant reduction in the risk of disease
recurrence by as much as 48 % in some trials [2, 3]. Since
its approval, trastuzumab has become the standard of care
for patients with HER2-positive breast cancer.
In 2014, the patent exclusivity rights for trastuzumab will
expire in Europe, opening the door for the creation of copy
versions. Unlike small-molecule drugs such as aspirin and
tyrosine kinase inhibitors, which are produced via chemical
synthesis, trastuzumab belongs to a unique class of agents
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known as biologics. Biologics are complex drugs that are
derived from living organisms such as bacterial and
eukaryotic cells [4]. Because of the size and complexity of
biologics and the variability introduced during production, it
is impossible to make an identical copy, or generic version,
of a biologic. Instead, copies of biological medicines are
known as ‘‘biosimilars,’’ a term that highlights the fact that
they are similar to the reference products but not entirely
identical. Importantly, only copies of biologics that have
undergone a comparability exercise and have been approved
by a regulatory body can be called ‘‘biosimilar’’ [5].
The first biosimilars introduced in Europe were biosimilar
somatropins in 2006. These were followed by biosimilar
erythropoietins in 2007 and biosimilar filgrastims starting in
2008 [6]. Until recently, only biosimilars of these lower
molecular-weight biologics were available in Europe. This
changed in September 2013 when the European Commis-
sion granted marketing authorization for two biosimilars of
the anti-tumor necrosis factor alpha (TNF-a) antibody inf-
liximab [7]. This represents the first time a biosimilar of a
monoclonal antibody (mAb) has been approved by a regu-
latory body. Currently, several biosimilar versions of trast-
uzumab are under development. It is expected that approval
of a biosimilar trastuzumab may come as early as 2014. If
so, biosimilar trastuzumab will be the first biosimilar mAb
available for the treatment of cancer. The development of
biosimilar trastuzumab represents a unique and exciting
opportunity in the field of breast cancer. In this review, we
will explore the development and approval of biosimilar
trastuzumab and discuss in detail a number of issues relevant
to breast oncologists when considering biosimilar trast-
uzumab for their patients.
Pathway to biosimilar trastuzumab approval
Guidelines for biosimilar mAb development
Biosimilars are approved on the basis of a regulatory path-
way different from both generics and originators. Because
biosimilars are the copies of molecules that have already
been approved through a rigorous clinical trial program, the
dossiers for their approval are reduced compared to those of
the originators. However, because they are not identical to
the reference products, biosimilars require more thorough
testing than generics. The European Medicines Agency
(EMA) has issued several guidelines regulating the devel-
opment of biosimilars, including guidelines for the devel-
opment and testing of biosimilar mAbs [8, 9]. Prior to being
approved, a biosimilar must demonstrate comparability to a
reference product in terms of quality characteristics, bio-
logical activity, safety, and efficacy. This is achieved
through a stepwise comparability exercise that includes
in vitro analytical testing, non-clinical comparative testing,
and one or more clinical trials [8].
A key component of the biosimilarity exercise is an
accelerated clinical trial program in which the pharmaco-
kinetics, clinical efficacy, clinical safety, and immunoge-
nicity of the biosimilar are compared to that of the
originator. According to the EMA, the goal of the clinical
trial program is to ‘‘demonstrate similar efficacy and safety
compared to the reference medicinal product, not patient
benefit per se, which has already been established by the
reference medicinal product’’ [8]. Throughout the clinical
trial program, all testing must be done in a sensitive and
homogenous patient population so that any differences
between the biosimilar and the originator can be easily
detected. Likewise, the clinical endpoint for these trials
should be sensitive to the detection of product-related dif-
ferences. The EMA recommends overall response rate
(ORR) or complete response (CR) rate as endpoints for
clinical efficacy studies of biosimilar mAbs in oncology, as
these endpoints are less likely than survival endpoints to be
influenced by factors such as previous lines of therapy and
tumor burden [8]. Very often biosimilar clinical trials are
carried out for only one or two of the reference drugs’
indications. The expectation is that if data from these trials
are robust and there is adequate justification, the biosimilar
may be approved for indications of the reference medicinal
product in which it has not been tested. Extrapolation of
indications is essential to the biosimilar concept and has led
to much controversy, as we will discuss in greater detail.
Clinical trials of biosimilar trastuzumab
The first biosimilar mAbs were approved in Europe in 2013,
and several biosimilar trastuzumab candidates are currently
in development. Of these, CT-P6, from the Korean manu-
facturer Celltrion, is the furthest along in the clinical
development pathway. CT-P6 in combination with paclit-
axel has demonstrated comparability to Herceptin plus
paclitaxel in a pooled analysis of data from a phase I/IIb
pharmacokinetics study [10] and a phase III efficacy and
safety study [11] in women with HER2-positive metastatic
breast cancer. CT-P6 demonstrated equivalent pharmacoki-
netics and a similar safety profile to Herceptin in the phase
I/IIb study [10]. In the phase III clinical efficacy and safety
trial, 475 women with previously untreated HER2-positive
metastatic breast cancer received either CT-P6 or Herceptin,
both in combination with paclitaxel. The primary endpoint
was ORR by independent review with a predefined equiv-
alence margin of 15 %. Time to treatment failure (TTF) and
cardiotoxicity as measured by LVEF were secondary end-
points. In the pooled analysis of the phase I/IIb and phase III
studies (Table 1) [11], the primary endpoint of equivalent
ORR at cycle 8 was met, with 56.6 % of patients responding
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to CT-P6 compared with 61.9 % of patients receiving Her-
ceptin. Time to treatment failure in responding patients was
11.07 versus 12.52 months (P = 0.0978). Time to treatment
failure data were not presented for the intent-to-treat popu-
lation. CT-P6 had a toxicity profile similar to that of Her-
ceptin with no statistically significant differences. To date,
no data on immunogenicity have been released. On the basis
of these data, Celltrion has submitted CT-P6 for approval in
Korea [12] and is expected to do so in Europe in 2014.
Though CT-P6 will likely be the first biosimilar trast-
uzumab approved in Europe, there are several other bio-
similar candidates close behind in development. Of
particular interest is the Pfizer biosimilar candidate PF-
05280014, which was compared to Herceptin in a phase I
pharmacokinetics study in healthy male volunteers. In this
trial, PF-05280014 demonstrated comparability to Herceptin
on the basis of serum concentration, area under the serum
concentration–time curve and secondary pharmacokinetic
parameters. There were similar incidences of adverse events
in each treatment arm and no unexpected immunogenicity
[13]. A phase III trial comparing PF-05280014 to Herceptin,
both in combination with paclitaxel, in women with HER2-
positive metastatic breast cancer is planned [14]. Several
other biosimilar trastuzumab candidates are also in phase III
trials (Table 2) [11, 14–18].
Considerations for biosimilar trastuzumab
development
Patient population
According to the EMA guidelines for biosimilar mAbs,
clinical trials must be carried out in a sufficiently sensitive
and homogenous population [8]. For trastuzumab biosim-
ilars tested in breast cancer, the metastatic setting may not
be a sufficiently sensitive and homogenous population.
Metastatic disease is a highly heterogeneous state that can
vary based on prior treatment, line of therapy, disease
burden, comorbidities, location of metastasis, and molec-
ular phenotype of metastatic cells. Because common breast
cancer treatments such as chemotherapy and radiotherapy
are associated with an immunosuppressive effect [19, 20],
women with metastatic disease are more likely to be
immunologically impaired. These women also have a
greater risk of developing secondary cancers as a result of
previous therapy [21, 22].
While breast cancer is by nature a highly heterogeneous
disease, early breast cancer represents a far more sensitive
and homogeneous population in which to carry out clinical
trials of a biosimilar trastuzumab. At this stage patients
have received the same treatments, have a reduced disease
Table 1 Results from CT-P6








Overall response rate, n (%) 138 (56.6 %) 143 (61.9 %)
Time to progression, months 11.07 12.52 0.0978
Change in target lesion size 62.5 % 62.4 % 0.8403
Serious adverse events (Cgrade 3), n 28 24 0.7048
All adverse events (Cgrade 3), n 110 107 0.7865
Cardiotoxicity (Cgrade 3), n 6 3 0.3539
Table 2 Biosimilar










Celltrion/CT-P6 NCT01084876 MBC ORR Global phase III trial completed [11, 15]
and applications for approval
forthcoming
Biocon N/A N/A N/A Completed in India; results pending [16]
BIOCAD/BCD-
022




NCT01901146 EBC pCR Enrollment temporarily halted [18]
Pfizer/PF-
05280014
N/A MBC N/A Planned [14]
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burden, and do not suffer the adverse events associated
with treatments received in later lines of therapy. Because
the goal of a biosimilar clinical trial is to detect any
differences between the biosimilar and the originator,
the heterogenous nature of metastatic disease, the risk
for secondary tumors, and the potential for immune
impairment make patients with metastatic breast cancer a
poor population for biosimilar clinical trials. Clinical
testing of biosimilar trastuzumab in patients with early
breast cancer will allow for a more careful and thorough
biosimilarity assessment.
Clinical trial endpoints
A second challenge for clinical trials of biosimilar trastuzumab
is the selection of clinical trial endpoints. While survival is
generally a preferred endpoint in oncology clinical trials, sur-
vival endpoints may not be appropriate for a biosimilar com-
parability trial as they can be influenced by confounding
factors such as tumor burden, disease status, and previous lines
of therapy. The EMA suggests response as an endpoint for
biosimilar trials [8]. Because trastuzumab directly impacts
patient survival, many oncologists may feel uncomfortable
using a biosimilar version that has not demonstrated a survival
benefit in clinical trial. While ORR may be a preferable end-
point for detecting differences between products, it is not
always associated with long-term improvements in patient
outcome [23, 24]. Pathologic complete response (pCR),
however, has been shown to correlate closely with improve-
ments in disease-free survival (DFS) and OS in patients with
early breast cancer [25]. Use of pCR as a primary endpoint in
early breast cancer follows EMA recommendations both for a
response endpoint and for clinical testing in a sensitive and
homogenous population. A good practice would be to carry out
biosimilar trastuzumab trials using these parameters with long-
term survival as a secondary endpoint.
Considerations for clinical practice
Extrapolation
Extrapolation of a biosimilar to indications for which it was
not tested during the clinical trial program is common practice
in Europe. Many of the currently available biosimilars were
approved in every indication of the originator after testing in a
single indication. For the recently approved biosimilar mAbs
RemsimaTM (Celltrion) and InflectraTM (Hospira), approval
was granted for all indications of the originator Remicade
(infliximab, Janssen) after a phase I trial in ankylosing spon-
dylitis and a phase III trial in rheumatoid arthritis. Extrapo-
lated indications include ulcerative colitis, Crohn’s disease,
psoriatic arthritis, and plaque psoriasis [26, 27]. According to
the EMA guidelines, extrapolation of biosimilar data to other
indications of the originator is allowed, provided the mecha-
nism of action is the same in each indication and/or adequate
scientific justification can be provided based on the totality of
evidence, including experience gained with the reference
product and good clinical efficacy and safety data for the
biosimilar [8]. The precise mechanism of action for trast-
uzumab is unknown. Several putative mechanisms of action
for trastuzumab have been identified, and it may be that any
combination of these mechanisms results in the antibody’s
efficacy. It is also likely that these mechanisms may contribute
differently for each indication of trastuzumab [28].
Indication extrapolation forms the basis of the biosimilar
concept, and without it there would be minimal financial
benefit associated with biosimilars [29]. Current opinion
regarding extrapolation of indications for biosimilar mAbs
holds that if the clinical efficacy and immunogenicity testing
are done in the most sensitive patient population, it would be
appropriate to extrapolate to other indications of the refer-
ence antibody [30]. For HER2-positive breast cancer, this
would mean clinical testing of a biosimilar trastuzumab in
the adjuvant or neoadjuvant setting, with extrapolation to
metastatic breast cancer. The converse, a biosimilar tested in
the metastatic setting extrapolated to early breast cancer,
would not be acceptable. As discussed above, the metastatic
setting does not allow for appropriate evaluation of immu-
nogenicity signals because many patients with metastatic
breast cancer are immune compromised. Extrapolating a
biosimilar trastuzumab tested in metastatic breast cancer to
early breast cancer means an increased risk of unpredictable
immune responses that could reduce efficacy and increase
adverse events. A trial in the neoadjuvant setting is highly
recommended in order to justify the use of biosimilar
trastuzumab in the adjuvant setting.
Labeling
All biologic manufacturers must submit a pharmacovigilance
plan as part of the marketing authorization application. This
plan comprises pre- and post-authorization immunogenicity
testing, a risk management plan based on safety issues iden-
tified during the clinical trials, and post-marketing safety
commitments such as targeted questionnaires, phase IV
studies, and specialized follow-up for long-term use [9, 31].
The goal of this plan is to identify any product-associated
safety risks not observed during clinical testing and provide a
framework to rapidly report and manage such incidences.
Central to the pharmacovigilance plan is the need to be
able to accurately trace which medicines a patient is given.
Many medicines are prescribed by international nonpropri-
etary name (INN), which provides information regarding the
composition and type of drug. For biologics and biosimilars,
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the situation is more complicated. Like generics, biosimilars
are given the same INN as the originator [32]. While generics
are identical to their originators, and in many cases can be
used interchangeably, biosimilars are not. When tracking the
adverse events and other safety concerns associated with a
biosimilar or biologic, it is of utmost importance that the
appropriate drug is identified. Thus, prescription by brand
name is recommended by several regulatory agencies within
Europe [33, 34] and by the EMA. Because of this, in 2013,
the summary of product characteristics, or label, of two
biologic products was altered to include the statement ‘‘in
order to improve the traceability of biological medicinal
products, the trade name of the administered product should
be clearly recorded (or stated) in the patient file’’ [35, 36]. It
is expected that this statement will be added to other biologic
labels in the future, including Herceptin’s.
The contents of the Herceptin label are of interest with
regard to biosimilar trastuzumab, because biosimilars cur-
rently receive very similar labels to those of their originators
[37]. The label for a biosimilar product may not identify that
it is a biosimilar, what clinical studies have been done to
validate its comparability, or which indications are extrap-
olated. This is worrisome, as it is essential that, when
administering any drug to a patient, a clinician have as much
information as possible about that. Information on compa-
rability trial data and extrapolation can be found in a bio-
similar medicine’s European Public Assessment Report.
However, this is difficult to access and interpret, and many
community physicians are not fully aware of the information
contained in this document. The label for each drug is the
primary source of information for the practicing clinician
and should be as clear and complete as possible. Because of
this, we recommend the label for any approved biosimilar
trastuzumab be altered to identify that the product is a bio-
similar. Importantly, the clinical trial data to justify com-
parability and extrapolation should be included. The
document should also be updated with results of the post-
approval pharmacovigilance activities once this information
is available [30].
Interchangeability, substitution, and switching
Interchangeability has been an issue of serious concern for
biosimilars since the approval of the first biosimilar medi-
cines nearly a decade ago. Because generic medicines are
therapeutically equivalent to their originators, they are often
considered interchangeable with the originators. Because
biosimilars are not therapeutically equivalent to their origi-
nators, many physicians feel strongly that biosimilars should
not be considered interchangeable. Others argue that inter-
changeability is essential to the incorporation of biosimilars
into clinical practice and is an obvious consequence of the
biosimilarity exercise [38]. Currently, each country in the
European Union (EU) is allowed to decide individually
which medicines are interchangeable.
Interchangeability becomes an issue when the traceability
of a biologic product is compromised through automatic
substitution or switching. When products are interchangeable,
the patient may receive either the biosimilar or the originator,
regardless of what the physician has prescribed and recorded.
If the patient later develops an adverse reaction to the drug, the
physician may incorrectly attribute the source because of this
automatic substitution. It is also possible that the patient may
be switched back and forth between the biosimilar and the
originator, either due to poor record keeping as a result of
automatic substitution or because the drugs are considered
interchangeable. Switching between two similar biologic
drugs increases the risk of anti-drug antibodies, which can lead
to adverse immunologic reactions and decreased drug effi-
cacy. Because the patient has received multiple drugs, the
origin of these adverse events cannot be traced.
There is no EU-wide policy on automatic substitution.
Automatic substitution is regulated at the national level and
varies by country [39]. Currently no country has passed
legislation allowing this practice with biologics, and many
have specifically prohibited it. We agree with this action, as
we feel that automatic substitution and switching with bio-
similars are risky behaviors that preclude successful phar-
macovigilance activities. A biosimilar trastuzumab will
never be therapeutically equivalent to the originator, and so
these medicines should not be considered interchangeable.
Because trastuzumab is used to prolong survival in patients
with a fatal disease, it is irresponsible to take risks that might
impair the efficacy and safety of the patients’ treatment.
The future of biosimilar trastuzumab in Europe
The eventual approval of a biosimilar trastuzumab in Europe
is certain and is not an outcome to be feared or prevented.
Less expensive treatments for patients and increased com-
petition for innovators will ultimately improve the state of
breast cancer treatment. However, before this eventuality
can occur, it is our responsibility as caregivers to ensure we
are protecting our patients’ interest and well-being. Here, we
have outlined several recommendations for the development
of biosimilar trastuzumab and suggestions for its use in
clinical practice. It is our hope that these recommendations
will serve as a guide for clinicians, pharmacists, regulators,
and biosimilar manufacturers as biosimilar trastuzumab is
incorporated into the European marketplace.
To summarize, it is our opinion that biosimilar trast-
uzumab candidates have many challenges to overcome
before approval. The majority of clinical trials involve
patients with metastatic breast cancer, which is not a sen-
sitive and homogenous population, and use endpoints that
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do not always correlate with survival. Using endpoints,
such as pCR in early breast cancer, which predict survival
would be preferable. When a biosimilar trastuzumab that
has been tested in early breast cancer is approved in Eur-
ope, extrapolation of the data to metastatic breast cancer
might be appropriate, assuming this is supported by the
marketing authorization application. However, if a bio-
similar trastuzumab were approved based on testing in
metastatic breast cancer, it would not be appropriate to
extrapolate to a potentially curable patient population such
as early breast cancer; this would require additional testing.
As with all biopharmaceuticals, biosimilar trastuzumab
will require thorough pharmacovigilance following autho-
rization. In order to facilitate this, physicians should pre-
scribe all biologics by brand name. This will avoid
confusion between an originator drug and a biosimilar, and
will also aid in preventing accidental substitution or
switching of medicines. Because biosimilars are not iden-
tical copies of their originator drugs, they should not be
considered interchangeable, and switching between these
medicines with or without the physician’s consent should
be avoided. We feel that a combination of good clinical
trial design and good post-approval practices will allow
biosimilar trastuzumab to become an important and trusted
component of breast cancer care.
Biosimilar trastuzumab may be the first biosimilar mAb
approved for oncology, but many others will soon follow.
Patents for several therapeutic antibodies expire in the next
5 years, and biosimilars of rituximab and bevacizumab are
already in development. All of the considerations for bio-
similar trastuzumab discussed here will apply for many of
these upcoming biosimilars. With that in mind, our final
and most important recommendation is for thorough edu-
cation of all parties involved in the biosimilar decision-
making process. Even as we enter our eighth year of bio-
similars in Europe, many key parties lack a basic under-
standing of what a biosimilar is, how it differs from a
generic, why these differences may or may not be impor-
tant, and how to minimize any perceived risk associated
with biosimilars. As we move toward a future where bio-
similars will be part of the treatment landscape for many
diseases, it is essential that we ensure our colleagues and
patients are properly educated on the subject. Adequate
education for all involved parties allows everyone involved
to make informed decisions based on knowledge, comfort,
and transparency rather than fear and confusion. This is the
keystone to ensure successful integration of biosimilar
mAbs into the treatment of cancer.
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